All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia
1. In this phase 1-2 trial involving patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy,...
1. In this phase 1-2 trial involving patients with newly diagnosed acute myeloid leukemia who were ineligible for intensive chemotherapy,...
1. In this randomized controlled trial, acute stroke patients with medium-vessel occlusion and moderate-to-severe neurological deficits who received thrombectomy in...
1. In this randomized controlled trial, household contacts of patients with Covid-19 who received ensitrelvir shortly after exposure had reduced...
1. In this interim analysis from a randomized controlled trial, adults with biopsy-proven IgA nephropathy and persistent proteinuria who received...
1. In adolescents and adults with hemophilia A, subcutaneous Mim8 prophylaxis reduced treated bleeding events versus on-demand therapy and versus...
1. In patients with presumptive pulmonary tuberculosis, the MiniDock MTB molecular test using sputum and tongue swabs showed diagnostic accuracy...
1. In two large randomized platform trials, early treatment with nirmatrelvir–ritonavir did not reduce hospitalization or death among mostly vaccinated,...
1. In clinically stable patients with prior intracerebral hemorrhage, a fixed-dose combination pill containing three low-dose antihypertensive agents reduced recurrent...
1. In this randomized controlled trial involving patients with recent noncardioembolic ischemic cerebrovascular accident, asundexian in combination with antiplatelet therapy...
1. In this randomized controlled trial involving children with newly diagnosed Kawasaki disease, adjunctive prednisolone did not reduce the incidence...
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in